1. Stocks
    2. /
  2. CSL Ltd (ASX: CSL)
    3. /

CSL Ltd (ASX: CSL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

CSL Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $84.09 billion
P/E Ratio 18.99
Dividend Yield 2.60%
Shares Outstanding 485.15 million
Earnings per share 6.170
Dividend per share 4.52
Year To Date Return 0.95%
Earnings Yield 5.27%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • CSL Ltd (ASX: CSL)
    Latest News

    Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
    Healthcare Shares

    Are CSL shares a buy after their heavy decline?

    | James Mickleboro

    Let's see what one broker is saying about the biotech giant.

    Read more »

    A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
    How to invest

    ASX sell-off accelerates: Is it time to sell shares?

    | Sebastian Bowen

    It might be tempting to hit the sell button on days like today...

    Read more »

    A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy ASX shares
    Healthcare Shares

    CSL, Sonic, and Sigma Healthcare shares: Buy, hold, or sell?

    | Bronwyn Allen

    Analysts share their ratings and opinions on 3 large-cap ASX 200 healthcare stocks.

    Read more »

    a close up of a man with wide open eyes and wide open mouth holding his head and reacting in shock and surprise to some share market ews.
    How to invest

    How to prepare for a share market crash… before it's too late

    | Samantha Menzies

    The ASX 200 Index is now down more than 3% from its October peak.

    Read more »

    young female doctor with digital tablet looking confused.
    Healthcare Shares

    Down 38% in a year, are CSL shares now a buy?

    | Bernd Struben

    A leading investment expert delivers his verdict on CSL shares.

    Read more »

    A couple cheers as they sit on their lounge looking at their laptop and reading about the rising Redbubble share price
    Share Market News

    5 top ASX ETFs to buy and hold for 5 years+

    | James Mickleboro

    Let's look at five ASX ETFs to build wealth with through to 2030 and beyond.

    Read more »

    A man takes his dividend and leaps for joy.
    Growth Shares

    3 proven ASX compounders that could double your money over time

    | James Mickleboro

    Want big returns for your portfolio? Here's why these shares could deliver the goods.

    Read more »

    Four investors stand in a line holding cash fanned in their hands with thoughtful looks on their faces.
    How to invest

    How to make your first $10,000 in the ASX share market

    | James Mickleboro

    Here's a guide for growing your wealth in the share market.

    Read more »

    View of a business man's hand passing a $100 note to another with a bank in the background.
    Share Market News

    Top 10 most-traded Australian shares last week

    | Samantha Menzies

    These stocks piqued investor interest.

    Read more »

    Broker written in white with a man drawing a yellow underline.
    Broker Notes

    Morgans names 3 ASX 200 shares to buy in November

    | James Mickleboro

    Let's see which shares the broker is bullish on right now.

    Read more »

    a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
    Share Market News

    CSL flags influenza growth at 2025 Capital Markets Day

    | Laura Stewart

    CSL showcases Seqirus revenue growth and market leadership at its 2025 Capital Markets Day in Chicago.

    Read more »

    A woman presenting company news to investors looks back at the camera and smiles.
    Blue Chip Shares

    3 high-quality ASX 200 blue chip shares to buy and hold for 10 years

    | James Mickleboro

    Brokers have put buy ratings on these big names recently.

    Read more »

    Frequently Asked Questions

    CSL was listed on the ASX in June 1994.

    CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent.

    Since 2021 CSL has paid an unfranked interim dividend in April and a 10% franked final dividend in September/October.

    CSL has a dividend reinvestment plan, however, it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.

    CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks, the adjusted entry price is equivalent to around 76 cents. 

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    09 Sep 2025 $2.4508 0.00% Final 03 Oct 2025
    10 Mar 2025 $2.0711 0.00% Interim 09 Apr 2025
    09 Sep 2024 $2.1746 0.00% Final 02 Oct 2024
    11 Mar 2024 $1.7989 0.00% Interim 03 Apr 2024
    11 Sep 2023 $2.0078 6.42% Final 04 Oct 2023
    09 Mar 2023 $1.6215 0.00% Interim 05 Apr 2023
    06 Sep 2022 $1.7583 10.00% Final 05 Oct 2022
    07 Mar 2022 $1.4229 0.00% Interim 06 Apr 2022
    02 Sep 2021 $1.5897 10.00% Final 30 Sep 2021
    04 Mar 2021 $1.3491 0.00% Interim 01 Apr 2021
    10 Sep 2020 $1.4696 0.00% Final 09 Oct 2020
    11 Mar 2020 $1.4713 0.00% Interim 09 Apr 2020
    10 Sep 2019 $1.4545 0.00% Final 11 Oct 2019
    13 Mar 2019 $1.2032 0.00% Interim 12 Apr 2019
    11 Sep 2018 $1.2782 0.00% Final 12 Oct 2018
    14 Mar 2018 $1.0050 0.00% Interim 13 Apr 2018
    12 Sep 2017 $0.0000 0.00% Final 13 Oct 2017
    15 Mar 2017 $0.8378 0.00% Interim 13 Apr 2017
    13 Sep 2016 $0.8867 0.00% Final 07 Oct 2016
    23 Mar 2016 $0.8147 0.00% Interim 15 Apr 2016
    07 Sep 2015 $0.8999 0.00% Final 02 Oct 2015
    16 Mar 2015 $0.7439 0.00% Interim 10 Apr 2015
    08 Sep 2014 $0.6485 0.00% Final 03 Oct 2014
    05 Mar 2014 $0.5888 0.00% Interim 04 Apr 2014
    09 Sep 2013 $0.5698 0.00% Final 04 Oct 2013
    05 Mar 2013 $0.3406 0.00% Interim 05 Apr 2013
    17 Sep 2012 $0.3290 0.00% Final 12 Oct 2012
    14 Mar 2012 $0.2520 0.00% Interim 13 Apr 2012
    19 Sep 2011 $0.3210 6.23% Final 14 Oct 2011
    08 Mar 2011 $0.2450 0.00% Interim 08 Apr 2011
    13 Sep 2010 $0.3308 15.96% Final 08 Oct 2010
    09 Mar 2010 $0.2450 0.00% Interim 09 Apr 2010
    14 Sep 2009 $0.2800 0.00% Final 09 Oct 2009
    17 Sep 2007 $0.4675 58.82% Final 12 Oct 2007
    14 Mar 2006 $0.1960 0.00% Interim 13 Apr 2006
    30 Aug 2005 $0.0753 23.64% Special 10 Oct 2005
    30 Aug 2005 $0.3000 100.00% Final 10 Oct 2005
    29 Mar 2004 $0.1200 100.00% Interim 13 Apr 2004

    CSL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About CSL Ltd

    CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.

    CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company is one of the largest on the ASX.

    CSL’s operational businesses include CSL Behring, CSL Seqirus and CSL Vifor. Its Plasma business operates one of the largest plasma collection networks in the world. CSL is recognised for its global leadership in three main areas: rare and serious diseases, vaccine development, and iron deficiency and nephrology (kidney research).

    The company operates in over 40 countries, predominantly Australia, the United States, Germany, the United Kingdom, and Switzerland.

     

    CSL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Jan 2026 $173.32 $-1.78 -1.02% 682,808 $175.01 $175.86 $173.32
    12 Jan 2026 $175.10 $0.81 0.46% 573,969 $174.50 $175.62 $174.00
    09 Jan 2026 $174.29 $-0.16 -0.09% 740,858 $175.00 $175.60 $173.47
    08 Jan 2026 $174.45 $4.45 2.62% 944,446 $175.10 $175.10 $172.00
    07 Jan 2026 $170.00 $1.71 1.02% 1,039,843 $168.80 $170.52 $168.65
    06 Jan 2026 $168.29 $-4.17 -2.42% 1,051,387 $172.50 $173.30 $168.29
    05 Jan 2026 $172.46 $0.50 0.29% 484,026 $172.01 $173.02 $171.75
    02 Jan 2026 $171.96 $-0.69 -0.40% 459,420 $173.50 $173.87 $171.90
    31 Dec 2025 $172.65 $0.23 0.13% 474,918 $172.50 $173.46 $172.00
    30 Dec 2025 $172.42 $-1.13 -0.65% 507,640 $173.70 $174.05 $172.04
    29 Dec 2025 $173.55 $2.07 1.21% 818,551 $172.50 $174.23 $171.75
    24 Dec 2025 $171.48 $-4.18 -2.38% 542,529 $175.60 $175.82 $171.48
    23 Dec 2025 $175.66 $-0.65 -0.37% 683,948 $176.90 $177.47 $175.59
    22 Dec 2025 $176.31 $1.23 0.70% 554,540 $178.20 $178.87 $175.54
    19 Dec 2025 $175.08 $1.09 0.63% 1,930,903 $175.00 $176.32 $174.72
    18 Dec 2025 $173.99 $0.60 0.35% 1,175,326 $173.09 $174.81 $171.64
    17 Dec 2025 $173.39 $-3.76 -2.12% 1,215,809 $176.12 $177.00 $172.55
    16 Dec 2025 $177.15 $-2.16 -1.20% 1,578,336 $179.77 $179.77 $177.15

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 Nov 2025 Brian Daniels Buy 3,400 $99,746
    On-market trade. US$, 1,700 ADRs (representing 3,400 ordinary shares)
    in CSL Limited.
    29 Oct 2025 Paul McKenzie Issued 58,360 $9,966,137
    As advised by the company. 140,520 Performance Share Units
    01 Sep 2025 Paul McKenzie Issued 8,101 $1,703,397
    Conversion of securities.
    01 Sep 2025 Paul McKenzie Exercise 8,101 $1,703,397
    Conversion of securities. 82,160 Performance Share Units
    01 Sep 2025 Paul McKenzie Sell 3,699 $772,402
    On-market trade.
    01 Sep 2025 Paul McKenzie Expiry 13,261 $2,788,390
    As advised by the company. Lapsed, 90,261 Rights
    27 Aug 2025 Samantha (Sam) Lewis Issued 305 $66,907
    Director remuneration. Weighted Average Price. 305 rights
    27 Aug 2025 Robert Cuthbertson Issued 366 $80,288
    Director remuneration. Weighted Average Price. 366 rights
    27 Aug 2025 Marie McDonald Issued 244 $53,525
    Director remuneration. Weighted Average Price. 244 rights
    27 Aug 2025 Carolyn Hewson Issued 488 $107,051
    Director remuneration. 488 Rights. Weighted Average Price
    27 Aug 2025 Alison Watkins Issued 427 $93,670
    Director remuneration. Weighted Average Price 427 rights
    27 Aug 2025 Brian McNamee Issued 866 $189,972
    Director remuneration. Weighted Average Price. 866 Rights
    27 Aug 2025 Megan Clark Issued 366 $80,288
    Director remuneration. 366 Rights. Weighted Average Price
    27 Aug 2025 Brian Daniels Issued 244 $53,525
    Director remuneration. Weighted Average Price of $219.368283
    364 rights
    27 Aug 2025 Elaine Sorg Issued 244 $53,525
    Director remuneration. Weighted Average Price. 416 Rights
    22 Aug 2025 Robert Cuthbertson Exercise 132 $28,591
    Conversion of securities.
    22 Aug 2025 Robert Cuthbertson Buy 132 $28,591
    Conversion of securities.
    22 Aug 2025 Brian McNamee Exercise 312 $67,579
    Conversion of securities.
    22 Aug 2025 Brian McNamee Buy 312 $67,579
    Conversion of securities.
    22 Aug 2025 Alison Watkins Exercise 154 $33,356
    Conversion of securities.
    22 Aug 2025 Alison Watkins Buy 154 $33,356
    Conversion of securities.
    22 Aug 2025 Carolyn Hewson Buy 176 $38,121
    Conversion of securities.
    22 Aug 2025 Carolyn Hewson Exercise 176 $38,121
    Conversion of securities.
    22 Aug 2025 Samantha (Sam) Lewis Buy 110 $23,826
    Conversion of securities.
    22 Aug 2025 Samantha (Sam) Lewis Exercise 110 $23,826
    Conversion of securities.
    22 Aug 2025 Marie McDonald Exercise 88 $19,060
    Conversion of securities.
    22 Aug 2025 Marie McDonald Buy 88 $19,060
    Conversion of securities.
    22 Aug 2025 Megan Clark Exercise 132 $28,591
    Conversion of securities.
    22 Aug 2025 Megan Clark Buy 132 $28,591
    Conversion of securities.
    17 Mar 2025 Megan Clark Buy 200 $50,012
    On-market trade.
    19 Feb 2025 Elaine Sorg Issued 172 $44,261
    Issue of securities. 172 Right
    19 Feb 2025 Brian Daniels Issued 120 $30,880
    Issue of securities. vwap, 120 rights
    19 Feb 2025 Megan Clark Exercise 132 $34,960
    Conversion of securities. 132 Rights
    19 Feb 2025 Megan Clark Buy 132 $34,960
    Conversion of securities.
    19 Feb 2025 Marie McDonald Buy 88 $23,306
    Conversion of securities.
    19 Feb 2025 Marie McDonald Exercise 88 $23,306
    Conversion of securities. 88 Rights
    19 Feb 2025 Samantha (Sam) Lewis Exercise 110 $29,133
    Conversion of securities. 110 Rights
    19 Feb 2025 Samantha (Sam) Lewis Buy 110 $29,133
    Conversion of securities.
    19 Feb 2025 Carolyn Hewson Buy 176 $46,613
    Conversion of securities.
    19 Feb 2025 Carolyn Hewson Exercise 176 $46,613
    Conversion of securities. 176 Rights
    19 Feb 2025 Alison Watkins Exercise 154 $40,786
    Cancellation of securities. 154 Rights
    19 Feb 2025 Alison Watkins Buy 154 $40,786
    Conversion of securities.
    19 Feb 2025 Brian McNamee Buy 313 $82,898
    Conversion of securities.
    19 Feb 2025 Brian McNamee Exercise 313 $82,898
    Conversion of securities. 312 Rights
    19 Feb 2025 Robert Cuthbertson Exercise 132 $34,960
    Conversion of securities. 132 Rights
    19 Feb 2025 Robert Cuthbertson Buy 132 $34,960
    Conversion of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Carolyn Judith Hewson Non-Executive Director Dec 2019
    Ms Hewson is a former investment banker with over 35 years of experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has financial markets, risk management and investment management expertise. She has long term non executive experience in a few sectors bringing experience and insight on strategy, capital management and portfolio optimization through cycles, financial and non financial risk, social value, organizational culture and the changing external environment. She is Chair of the Corporate Governance Committee, Member of the Risk Management Committee, Member of the Human Resources Committee.
    Ms Alison Mary Watkins Non-Executive Director Aug 2021
    Ms Watkins brings experience through the executive and non executive roles she has held across industries, including manufacturing, agriculture, consumer goods, retail and financial services. She is a Member of the Reserve Bank Monetary Policy Board (since March 2025) and 2025). She is Chair of the Risk Management Committee, Member of the Human Resources Committee, Member of the Corporate Governance Committee and a Member of the Disclosure Committee.
    Dr Brian Anthony McNamee Non-Executive DirectorNon-Executive Chairman Jan 1990
    Dr McNamee has executive experience in the biopharmaceutical industry, with a focus on strategy. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued several private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. He is a Member of the Innovation and Development Committee, Member of the Disclosure Committee, Member of the Corporate Governance Committee.
    Dr Robert Andrew Cuthbertson Non-Executive Director Oct 2018
    Professor Cuthbertson has over 35 years of experience in medical research and biotech development with large biopharmaceutical companies and medical organizations. He also has non executive director experience. Prior to CSL, he was a senior scientist at Genentech Inc., a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicine for people with life threatening diseases. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is Chair of the Innovation and Development Committee, Member of the Corporate Governance Committee.
    Ms Samantha (Sam) Louise Lewis Non-Executive Director Jan 2024
    Ms Lewis has experience in accounting, finance, auditing, risk management, corporate governance, capital markets and due diligence. Prior to becoming a Non executive Director, Ms Lewis spent 24 years with Deloitte, including 14 years as a Partner from 2000 until 2014. In that role, she acted as lead auditor of several major Australian listed entities and provided accounting and transactional advisory services including due diligence, IPOs and debt/equity raisings. Ms Lewis has experience of working with companies in the manufacturing, retail and industrial sectors. She is currently a Non-executive Director at APA Group Limited and Australia Pacific Airports Corporation Limited.
    Mr Gordon Naylor Non-Executive Director Dec 2025
    --
    Dr Paul McKenzie Chief Operating OfficerExecutive DirectorChief Executive OfficerManaging Director Dec 2022
    Dr McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organizations. Prior to joining CSL, Dr McKenzie was executive vice president of Pharmaceutical Operations & Technology at Biogen. He also served in a range of senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol Myers Squibb and Merck. He is a Member of the Innovation and Development Committee.
    Ms Elaine Sorg Non-Executive Director Sep 2024
    Ms Sorg has more than 35 years of experience as a senior executive with leading pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was Senior Vice President for AbbVie and President of AbbVie's US commercial operations. Ms Sorg's experience extends across biopharmaceutical industry and brands across therapeutic areas as well as segments. She is a Member of the Innovation and Development Committee.
    Dr Brian Daniels Non-Executive Director Dec 2024
    Dr Daniels has over 30 years of experience in clinical development, medical affairs, commercialization and biotech investing. Dr Daniels is currently a partner at 5AM Ventures, joining as a Venture Partner in 2014 and becoming a Partner in 2018. Dr Daniels spent more than 20 years in clinical drug development, including leading the Development and Medical Affairs division at Bristol-Myers Squibb. He directed the development of numerous innovative medicines across several therapeutic areas including in Cardio Vascular, Virology and Oncology. He is a Member of the Innovation and the Development Committee.
    Mr Cameron Bruce Price Non-Executive Director Oct 2025
    Mr. Price will shortly retire as General Counsel & Chief Risk Officer at the Future Fund, Australia's
    Sovereign Wealth Fund, which manages the global investment of several funds including the
    $240 billion Future Fund and the $24 billion Medical Research Future Fund. He held this role
    for 11 years. Prior to that Cameron was a senior commercial lawyer, partner and Board member
    at Allens specialising in mergers & acquisitions, equity capital markets and corporate
    governance and compliance.
    Mr Constantine Saroukos Non-Executive Director Dec 2025
    --
    Ms Fiona Mead Company SecretaryHead of Group Governance Jun 2018
    -
    Kate Priestman Chief Corporate & External Affairs Officer
    -
    Joy Linton Chief Financial Officer
    -
    Roanne Parry Chief Human Resources Officer
    -
    Mary Oates Chief Operating Officer
    -
    Fiona Mead Company SecretaryHead of Group Governance
    -
    Ken Lim Executive Vice President and Chief Strategy Officer
    -
    Andy Schmeltz Executive Vice President CSL Behring
    -
    Mark Hill Executive Vice President Chief Digital Information Officer
    -
    Bill Mezzanotte Executive Vice President Head of Research & Development and Chief Medical Officer
    -
    Greg Boss Executive Vice President Legal and CSL Group General Counsel
    -
    Herve Gisserot Senior Vice President and General Manager CSL Vifor
    -
    Dave Ross Senior Vice President and General Manager CSL Seqirus
    -
    John Levy Senior Vice President Enterprise Accelerator
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 166,361,570 34.36%
    J P Morgan Nominees Australia Pty Limited 83,504,097 17.25%
    Citicorp Nominees Pty Limited 49,704,198 10.26%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 11,954,183 2.47%
    BNP Paribas Noms Pty Ltd 8,982,224 1.86%
    National Nominees Limited 5,141,190 1.06%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 3,653,663 0.75%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 3,494,546 0.72%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,363,436 0.69%
    Netwealth Investments Limited <Wrap Services A/C> 3,342,620 0.69%
    Australian Foundation Investment Company Limited 2,318,500 0.48%
    Solium Nominees (Australia) Pty Ltd <Allocated A/C> 1,773,344 0.37%
    Custodial Services Limited <Beneficiaries Holding A/C> 1,465,611 0.30%
    Mutual Trust Pty Ltd 1,436,680 0.30%
    Argo Investments Limited 1,351,509 0.28%
    HSBC Custody Nominees (Australia) Limited i 1,206,548 0.25%
    BNP Paribas Noms (Nz) Ltd 1,041,467 0.22%
    Solium Nominees (Australia) Pty Ltd <Vsa A/C> 1,022,296 0.21%
    UBS Nominees Pty Ltd 984,834 0.20%
    D W S Nominees Pty Ltd 793,208 0.16%

    Profile

    since

    Note